{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:12:15Z","timestamp":1776147135821,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Paroxetine, a selective serotonin reuptake inhibitor widely used in the management of major depressive disorders and other psychiatric disorders, remains insufficiently characterized regarding its adverse event spectrum. Thus, this study wanted to conduct a comprehensive evaluation of its post-marketing safety profile by analyzing reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse event data related to paroxetine were extracted from the FAERS spanning the period from the first quarter of 2004 through the second quarter of 2025. Demographic distributions and reporter characteristics were analyzed to describe the exposed population. Signal detection was performed using four established disproportionality algorithms, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 39,404 adverse event reports associated with paroxetine were included in the analysis. Female patients accounted for the majority of cases (57.41%), followed by males (32.84%). The most frequently reported preferred term (PT) was \u201cdrug withdrawal syndrome,\u201d categorized under systemic diseases and administration site conditions, with 6,601 cases. This event demonstrated strong positive signals across all disproportionality metrics (ROR = 27.27, PRR = 26.31, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      = 148,641, IC = 4.61, EBGM = 23.47). The highest signal strengths were observed within the SOC of congenital, familial, and genetic disorders. Notably, the PT \u201ccarcinogenic effect on offspring,\u201d although reported only three times, exhibited markedly elevated values (ROR = 952.54, PRR = 952.52, \u03c7\n                      <jats:sup>2<\/jats:sup>\n                      = 712.89, IC = 7.90, EBGM = 238.88), indicating an extremely disproportionate reporting frequency compared with baseline levels. Most adverse events (12.49%) appeared within the first 30 days of paroxetine therapy prescription.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pharmacovigilance assessment of paroxetine systematically identified significant safety signals. These findings provide important post-marketing evidence to strengthen drug safety surveillance and facilitate more informed, patient-centered therapeutic decisions in clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1744180","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:36Z","timestamp":1776144996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"17","author":[{"given":"Santosh","family":"Chokkakula","sequence":"first","affiliation":[{"name":"Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute","place":["Cheongju, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Rhinology, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Oncology Department 4, The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawaher","family":"Bin Jumah","sequence":"additional","affiliation":[{"name":"Nursing Administration & Education Department, College of Nursing, King Saud University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bommireddy","family":"Naveen","sequence":"additional","affiliation":[{"name":"Department of Chemical and Biological Engineering, Gachon University","place":["Seongnam-Si, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University","place":["Tianjin, China"]},{"name":"Department of Medical and Nursing Science, International College, Krirk University","place":["Bangkok, Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"B1","article-title":"Diagnostic and statistical manual of mental disorders","volume-title":"Text revision","year":"2022"},{"key":"B2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.64719\/pb.4155","article-title":"Brief report: paroxetine in younger and adult individuals at high risk for suicide","volume":"39","author":"Bauer","year":"2006","journal-title":"Psychopharmacol. Bulletin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/bcp.12849","article-title":"The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis","volume":"81","author":"B\u00e9rard","year":"2016","journal-title":"Br. Journal Clinical Pharmacology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/bcp.12898","article-title":"Meta-analysis requires independent observations and freedom from bias","volume":"81","author":"Bracken","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"11706","DOI":"10.4088\/JCP.08m04927blu","article-title":"Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials","volume":"72","author":"Carpenter","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1399493","DOI":"10.3389\/fpsyt.2024.1399493","article-title":"National patterns of paroxetine use among US medicare patients from 2015\u20132020","volume":"15","author":"Cavanah","year":"2024","journal-title":"Front. Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with selective serotonin reuptake inhibitors (SSRIs): analysis of both the european EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-244X-4-16","article-title":"Three-year naturalistic outcome study of panic disorder patients treated with paroxetine","volume":"4","author":"Dannon","year":"2004","journal-title":"BMC Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1192\/bjp.2024.194","article-title":"Real-world effects of antidepressants for depressive disorder in primary care: population-based cohort study","volume":"226","author":"De Crescenzo","year":"2025","journal-title":"Br. J. Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol. Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1177\/0891988703255689","article-title":"Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"16","author":"Fabian","year":"2003","journal-title":"J. Geriatr. Psychiatry. Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"21831","DOI":"10.4088\/JCP.19com12794","article-title":"Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs","volume":"80","author":"Fava","year":"2019","journal-title":"J. Clin. Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"key":"B15","first-page":"1","article-title":"Poisoning suicide due to paroxetine overdose toxicity, aided by benzodiazepine and antipsychotic drugs","author":"Florou","year":"2025","journal-title":"Int. J. Leg. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2165\/00023210-199708020-00010","article-title":"Paroxetine: a review of its pharmacology and therapeutic potential in the management of panic disorders","volume":"8","author":"Foster","year":"1997","journal-title":"CNS Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1001\/jama.2017.3828","article-title":"Depression is the leading cause of disability around the world","volume":"317","author":"Friedrich","year":"2017","journal-title":"Jama"},{"key":"B18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0014-2999(02)02557-8","article-title":"Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine","volume":"454","author":"Fujishiro","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003495-199855010-00007","article-title":"Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders","volume":"55","author":"Gunasekara","year":"1998","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S2215-0366(24)00133-0","article-title":"Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"11","author":"Henssler","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1517\/13543784.8.4.417","article-title":"Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders","volume":"8","author":"Heydorn","year":"1999","journal-title":"Expert Opin. Investig. Drugs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms","volume":"6","author":"Horowitz","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/jamapsychiatry.2017.3644","article-title":"Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium","volume":"75","author":"Huybrechts","year":"2018","journal-title":"JAMA Psychiatry."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e50691","DOI":"10.7759\/cureus.50691","article-title":"Unexpectedly prolonged serotonin syndrome and fatal complications following a massive overdose of paroxetine controlled-release","volume":"15","author":"Inoue","year":"2023","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jamapsychiatry.2025.1362","article-title":"Incidence and nature of antidepressant discontinuation symptoms: a systematic review and meta-analysis","volume":"82","author":"Kalfas","year":"2025","journal-title":"JAMA Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2165\/00003495-200767120-00001","article-title":"Pharmacotherapy of mood disorders and treatment discontinuation","volume":"67","author":"Lader","year":"2007","journal-title":"Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0140-6736(22)02080-3","article-title":"Novel and emerging treatments for major depression","volume":"401","author":"Marwaha","year":"2023","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1017\/S2045796020000633","article-title":"Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries","volume":"29","author":"McGrath","year":"2020","journal-title":"Epidemiol. Psychiatric. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1017\/s092493380000417x","article-title":"A review of the safety of paroxetine","volume":"8","author":"Montgomery","year":"1993","journal-title":"Eur. Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.64719\/pb.4345","article-title":"Paroxetine, the antidepressant from hell? Probably not, but caution is required","volume":"46","author":"Nevels","year":"2016","journal-title":"Psychopharmacol. Bulletin"},{"key":"B31","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/jgf2.137","article-title":"Paroxetine-induced QTc prolongation","volume":"18","author":"Otsuka","year":"2017","journal-title":"J. General Fam. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3479564","article-title":"Understanding the delivery of collectively built protocols in an online health community for the discontinuation of psychiatric drugs","volume":"5","author":"Papoutsaki","year":"2021","journal-title":"Proc. ACM Human-Computer Interact."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.3390\/ijms24031904","article-title":"The antidepressant paroxetine reduces the cardiac sodium current","volume":"24","author":"Plijter","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s13256-025-05602-7","article-title":"Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report","volume":"19","author":"P\u00fctz","year":"2025","journal-title":"J. Med. Case Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"h3190","DOI":"10.1136\/bmj.h3190","article-title":"Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports","volume":"351","author":"Reefhuis","year":"2015","journal-title":"Bmj"},{"key":"B36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/TCRM.S395449","article-title":"Discontinuation of antidepressants in older adults: a literature review. Therapeutics and clinical risk management","volume":"19","author":"Romdhani","year":"2023","journal-title":"Ther. Clin. Risk Manag."},{"key":"B37","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jamapsychiatry.2013.684","article-title":"Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis","volume":"70","author":"Ross","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"B38","first-page":"1","article-title":"Do sex and gender matter in the pharmacological treatment of depression? naunyn-schmiedeberg's archives of pharmacology","author":"Seifert","year":"2025"},{"key":"B39","unstructured":"Paroxetine\n          \n          \n            \n              Shrestha\n              P.\n            \n            \n              Fariba\n              K. A.\n            \n            \n              Abdijadid\n              S.\n            \n          \n          Treasure Island, FL\n          StatPearls Publishing\n          StatPearls [Internet]\n          \n          2023"},{"key":"B40","volume-title":"Essential psychopharmacology: neuroscientific basis and practical applications","author":"Stahl","year":"2000"},{"key":"B41","article-title":"Suicidality in children and adolescents being treated with antidepressant medications","year":"2004"},{"key":"B42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3949\/ccjm.87a.19054","article-title":"Perinatal depression: a review","volume":"87","author":"Van Niel","year":"2020","journal-title":"Cleve Clin. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1046\/j.1365-2125.1999.00872.x","article-title":"Incidence and risk factors for hyponatremia following treatment with fluoxetine or paroxetine in elderly people","volume":"47","author":"Wilkinson","year":"1999","journal-title":"Br. Journal Clinical Pharmacology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2017.05.003","article-title":"A systematic review and meta-regression of the prevalence and incidence of perinatal depression","volume":"219","author":"Woody","year":"2017","journal-title":"J. Affect. Disord."},{"key":"B45","article-title":"Suicide. WHO fact sheet","year":"2024"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1744180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:36:38Z","timestamp":1776144998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1744180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":45,"alternative-id":["10.3389\/fphar.2026.1744180"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1744180","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1744180"}}